Variant classification, cancer syndrome criteria, and genomic risk models.
10
Clinical Tools
6
Clinical Domains
10
Conditions Covered
4
Guidelines Referenced
Clinical Context
Hereditary cancer syndrome identification is critical for risk-reducing interventions. The Amsterdam II criteria and Revised Bethesda guidelines identify individuals at risk for Lynch syndrome (hereditary non-polyposis colorectal cancer), guiding tumor testing for microsatellite instability (MSI) and germline genetic testing.
Clinical variant interpretation follows the ACMG/AMP 2015 guidelines, which classify sequence variants into five categories (Pathogenic, Likely Pathogenic, Uncertain Significance, Likely Benign, Benign) using a standardized framework of population data, computational data, functional data, and segregation data.
Pharmacogenomic tools including phenotype-to-dose adjustment calculators for TPMT/NUDT15 (thiopurine dosing), CYP2C19 (clopidogrel metabolism), and CYP2D6 (tamoxifen metabolism) support precision prescribing and reduce adverse drug events in genetically susceptible patients.
Conditions & Domains
Evidence Base